Can't I stop taking Tofacitinib/Shangjie once I take it?
Tofacitinib/Shangjie(Tofacitinib), as a JAK inhibitor, is widely used to treat rheumatoid arthritis, psoriatic arthritis and other immune system diseases. It reduces the immune response by inhibiting the activity ofJAK enzyme, thereby slowing down the progression of the disease and improving the patient's joint function and quality of life. However, many patients have questions about whether tofacitinib can be discontinued at will, especially after remission.

Once I take tofacitinib, can I stop taking it? The answer to this question is not absolute and depends mainly on the patient's condition, response to treatment, and the specific guidance of the doctor. In some cases, patients may experience significant symptom improvement during treatment, with relief from arthritis pain, swelling, and stiffness. At this point, patients may think they can stop taking the medication or reduce the dose, but in fact, this is not recommended.
First of all, when tofacitinib is used to treat immune diseases, it works by suppressing the excessive response of the immune system to slow down the progression of the disease. If the drug is stopped suddenly, the patient's immune system may revert to its original state and symptoms of the disease may return quickly. Therefore, discontinuation or dosage adjustment must be done under the guidance of a physician and not at your own discretion.
In addition, patients taking tofacitinib for a long period of time may be at risk for disease activity after discontinuation of the drug. For diseases such as rheumatoid arthritis, continued immunosuppressive therapy is key to maintaining symptom remission and preventing disease recurrence. If the patient stops taking the drug suddenly, especially if the dose is gradually reduced without medical guidance, the disease may rebound quickly and the symptoms may even be more severe than before the drug was stopped.
In addition, the safety and efficacy of tofacitinib during use also need to be monitored through regular inspections and evaluations.
Reference materials:https://www.xeljanz.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)